Why did Amneal Pharmaceuticals (AMRX) stock move recently?

On 7/28/2026, Amneal Pharmaceuticals moved +3.7% — No specific catalyst identified in today's credible coverage or filings; the move appears to reflect ongoing momentum from recent generic portfolio expansions (e.g., Iohexol/OMNIPAQUE) and pre-earnings positioning ahead of Q2 results on July 30. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Amneal Pharmaceuticals (AMRX) overvalued or fairly valued?

MarketChacha shows Amneal Pharmaceuticals's valuation in context — a trailing P/E of about 40.4, a forward P/E of about 15.3, a price-to-book of about 178.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Amneal Pharmaceuticals's revenue?

Amneal Pharmaceuticals reported revenue of $3.0B for FY2025, with net profit of $72.1M, per official filings.

What is the share price of Amneal Pharmaceuticals (AMRX)?

Amneal Pharmaceuticals last traded at $18.19 (-1.2% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Amneal Pharmaceuticals

AMRX · NYSE · Healthcare · United States

Snapshot

TickerAMRX

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees8,700

HeadquartersBridgewater, United States

Websitewww.amneal.com

Filings tracked20

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Who owns it

Insiders52.2%
Institutions47.8%
Public & other0.0%

418 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.67%
TPG GP A, LLC4.02%
Vanguard Portfolio Management LLC3.96%
Rubric Capital Management LP3.32%
Vanguard Capital Management LLC2.52%
State Street Corporation2.40%
Dimensional Fund Advisors LP1.89%
Geode Capital Management, LLC1.68%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -424.6% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-3.5% → 2.4%

Margin has expanded by about 5.9 points — the business is getting more profitable.

Return on equity-424.6%

Latest ROE of -424.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $824.7M · EPS 0.23

Est. earnings growth +11.0%

Next fiscal year

Rev $3.4B · EPS 1.20

Est. earnings growth +19.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$3.0B

Net margin

2.4%

Revenue CAGR (2y)

+12.3%

EPS (FY2025)

0.22

Net profit (FY2025)

$72.1M

Ask MarketChacha about AMRX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
No specific catalyst identified in today's credible coverage or filings; the move appears to reflect ongoing momentum from recent generic portfolio expansions (e.g., Iohexol/OMNIPAQUE) and pre-earnings positioning ahead of Q2 results on July 30.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$3.0B	$72.1M	0.22	2.4%	—
FY2024	$2.8B	$-116.9M	-0.38	-4.2%	—
FY2023	$2.4B	$-84.0M	-0.48	-3.5%	-424.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$796.2M	$57.7M	0.18	7.2%
2026Q1	$722.5M	$62.3M	0.19	8.6%
2025Q3	$784.5M	$2.4M	0.01	0.3%
2025Q2	$724.5M	$22.4M	0.07	3.1%
2025Q1	$695.4M	$12.2M	0.04	1.8%
2024Q3	$702.5M	$-156,000	0.00	-0.0%
2024Q2	$701.8M	$6.0M	0.02	0.9%
2024Q1	$659.2M	$-91.6M	-0.30	-13.9%
2023Q3	$620.0M	$9.7M	0.06	1.6%
2023Q2	$599.0M	$11.9M	0.08	2.0%
2023Q1	$557.5M	$-6.9M	-0.05	-1.2%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Completion of acquisition/disposition, Material financial obligation, Unregistered equity sale, Reg FD disclosure, Exhibits
SEC8/10/2026material
10-Q filing
SEC8/6/2026
8-K — Material agreement
SEC8/3/2026material
8-K — Shareholder vote results
SEC7/31/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/30/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
8-K — Shareholder vote results
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Material agreement, Results of operations, Unregistered equity sale, Reg FD disclosure, Exhibits
SEC4/22/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/27/2026material
10-K filing
SEC2/27/2026
8-K — Material agreement, Material financial obligation
SEC2/3/2026material
8-K — Other events
SEC1/28/2026material
8-K — Results of operations, Reg FD disclosure
SEC1/13/2026material

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/30/2025material
10-Q filing
SEC8/7/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/5/2025material
8-K/A — Shareholder vote results
SEC8/5/2025
8-K — Material agreement, Material financial obligation, Exhibits
SEC8/1/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.